FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285499> ?p ?o ?g. }

• W4379285499 endingPage "e13081" @default.
• W4379285499 startingPage "e13081" @default.
• W4379285499 abstract "e13081 Background: Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (MBC) are usually treated with endocrine therapy (ET) in combination with cyclin dependent kinase (CDK4/6) inhibitors. Such combinations have significantly improved treatment outcomes. HER2-negative MBC have recently been divided into two subgroups: HER2-zero, with an immunohistochemistry (IHC) score of 0, and HER2-low, with an IHC score of 1+ or 2+ and a negative in situ hybridization (ISH) assay. The aim of this meta-analysis is to compare treatment outcomes of these two groups of MBC patients when treated with a combination of ET and CDK4/6 inhibitors. Methods: A systematic literature review was conducted to identify relevant studies on the level of HER2 expression in breast cancer patients treated with CDK4/6 inhibitors. The review included articles in databases such as Medline via PubMed, Embase, and Cochran Library, as well as abstracts from the ASCO meeting and SABCS conference updated tell January 2023. Eligible studies included randomized controlled trials, prospective or retrospective studies, and case-control studies that compared the difference in PFS between HER2-low and HER2-zero among breast cancer patients treated with CDK4/6 inhibitors in first-line or beyond setting. A meta-analysis was performed to determine the pooled hazard ratio for progression-free survival (PFS). In addition, a pooled survival curve was created by digitizing the Kaplan-Meier curves to create pseudo-individual patients’ data following the methodology outlined by Combescure et. al (2014). Results: In total, 7 different studies were identified that included a total of 1,341 patients. The random effect model shows a statically significant shorter PFS in the HER2-low group; 17.2 months compared to 24.0 months in HER2-zero group (HR=1.55; 95% CI [1.27-1.84]; p <0.001). There was no statically significant heterogeneity between the studies (I 2 =51% p-value=0.07). The PFS rates at 12, 24, 36, and 48 months for HER2-low were as follow: (66.2%; 95% CI [50.0%-87.5%]), (33.2 %; 95% CI= 17.4%-63.4%), (26.2%; 95% CI= 12.8%-53.38%), and (22.05%; CI95%= 10.32%-47.12%), respectively compared to: (77.73%; 95% CI= 64.45%-93.75%), (50.00%; 95% CI= 34.66%-72.13%),(43.58%; 95% CI= 22.91%-82.89%), and (36.85%; 95% CI= 17.60%-77.15%) among patients with HER2-zero. Conclusions: In patients with MBC treated with CDK4/6 inhibitors, level of HER2 negativity may affect treatment outcomes; patients with HER2-zero had better PFS compared to those with HER2-low disease. Such findings, if confirmed in larger studies, may change the landscape of treatment of this group of patients." @default.
• W4379285499 created "2023-06-05" @default.
• W4379285499 creator A5032290025 @default.
• W4379285499 creator A5042005978 @default.
• W4379285499 creator A5057116628 @default.
• W4379285499 creator A5062675922 @default.
• W4379285499 creator A5064101656 @default.
• W4379285499 date "2023-06-01" @default.
• W4379285499 modified "2023-10-14" @default.
• W4379285499 title "Differences in treatment outcomes in relation to level of human epidermal growth factor receptor-2 (HER2) expression, HER2-low vs HER2-zero, in patients with hormone receptor-positive metastatic breast cancer treated with cyclin dependent kinase CDK4/6 inhibitors: A systematic review and meta-analysis." @default.
• W4379285499 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e13081" @default.
• W4379285499 hasPublicationYear "2023" @default.
• W4379285499 type Work @default.
• W4379285499 citedByCount "0" @default.
• W4379285499 crossrefType "journal-article" @default.
• W4379285499 hasAuthorship W4379285499A5032290025 @default.
• W4379285499 hasAuthorship W4379285499A5042005978 @default.
• W4379285499 hasAuthorship W4379285499A5057116628 @default.
• W4379285499 hasAuthorship W4379285499A5062675922 @default.
• W4379285499 hasAuthorship W4379285499A5064101656 @default.
• W4379285499 hasConcept C121608353 @default.
• W4379285499 hasConcept C126322002 @default.
• W4379285499 hasConcept C143998085 @default.
• W4379285499 hasConcept C207103383 @default.
• W4379285499 hasConcept C23589133 @default.
• W4379285499 hasConcept C2775930923 @default.
• W4379285499 hasConcept C2776694085 @default.
• W4379285499 hasConcept C2780739268 @default.
• W4379285499 hasConcept C2908728163 @default.
• W4379285499 hasConcept C29456083 @default.
• W4379285499 hasConcept C44249647 @default.
• W4379285499 hasConcept C530470458 @default.
• W4379285499 hasConcept C71924100 @default.
• W4379285499 hasConceptScore W4379285499C121608353 @default.
• W4379285499 hasConceptScore W4379285499C126322002 @default.
• W4379285499 hasConceptScore W4379285499C143998085 @default.
• W4379285499 hasConceptScore W4379285499C207103383 @default.
• W4379285499 hasConceptScore W4379285499C23589133 @default.
• W4379285499 hasConceptScore W4379285499C2775930923 @default.
• W4379285499 hasConceptScore W4379285499C2776694085 @default.
• W4379285499 hasConceptScore W4379285499C2780739268 @default.
• W4379285499 hasConceptScore W4379285499C2908728163 @default.
• W4379285499 hasConceptScore W4379285499C29456083 @default.
• W4379285499 hasConceptScore W4379285499C44249647 @default.
• W4379285499 hasConceptScore W4379285499C530470458 @default.
• W4379285499 hasConceptScore W4379285499C71924100 @default.
• W4379285499 hasIssue "16_suppl" @default.
• W4379285499 hasLocation W43792854991 @default.
• W4379285499 hasOpenAccess W4379285499 @default.
• W4379285499 hasPrimaryLocation W43792854991 @default.
• W4379285499 hasRelatedWork W2006323479 @default.
• W4379285499 hasRelatedWork W2037999876 @default.
• W4379285499 hasRelatedWork W2070780645 @default.
• W4379285499 hasRelatedWork W2131551233 @default.
• W4379285499 hasRelatedWork W2622612196 @default.
• W4379285499 hasRelatedWork W2767972188 @default.
• W4379285499 hasRelatedWork W2971304898 @default.
• W4379285499 hasRelatedWork W3082370759 @default.
• W4379285499 hasRelatedWork W4283528480 @default.
• W4379285499 hasRelatedWork W4309486417 @default.
• W4379285499 hasVolume "41" @default.
• W4379285499 isParatext "false" @default.
• W4379285499 isRetracted "false" @default.
• W4379285499 workType "article" @default.